On Tuesday, ResMed Inc. (NYSE:RMD)’s shares declined -2%, and closed at $72.41, hitting new 52-week high of $75.33, as ResMed will report its third quarter of fiscal year 2015 results on Thursday, April 23, 2015, after the New York Stock Exchange market close. A press release with ResMed’s results will be issued after 1:00 p.m. US Pacific Time and the corporation will host a webcast to talk about operating results and future outlook.
The earnings call is planned to start at 1:30 p.m. US Pacific Time and the live webcast of the call can be accessed on ResMed’s Investor Relations website at http://investor.resmed.com. Please go to this section of the website and click on the icon for the “Q3 2015 earnings webcast.”
ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and administration of respiratory disorders, with a focus on sleep-disordered breathing. Its products portfolio comprises airflow generators, diagnostic products, mask systems, motors, and headgear, in addition to other accessories, such as cold passover humidifiers, carry bags, and breathing circuits; and humidifiers comprising H5i and H4i, which connect with the continuous and variable positive airway pressure, and AutoSet flow generators to humidify and heat the air delivered to the patient to prevent the drying of nasal passages.
DDR Corp. (NYSE:DDR)’s shares dropped -1.99%, and settled at $18.71, during the last trading session on Tuesday, as on April 1, DDR Corp., declared that it closed on the attainment of one shopping center valued at $49 million and the disposition of 31 assets totaling $353 million at 100% ownership, or $153 million at the Corporation’s share, during the first quarter of 2015.
Included in the total transactional activity for the quarter is the final dissolution of the Corporation’s joint venture with Coventry Real Estate Advisors (“Coventry”). DDR transferred to Coventry its 20% interest in 21 of the joint venture’s remaining 22-asset portfolio, valued at $49 million at the Corporation’s share, and concurrently eliminated the Corporation’s $36 million of pro rata joint venture debt. DDR had no GAAP economic interest in 18 of the 22 assets at the time of dissolution. In exchange for its interest in the portfolio, Coventry transferred to DDR its 80% interest in Buena Park Place, a 223,000-square-foot power center located in Orange County, California, valued at $39 million, and concurrently stepped down $26 million of debt that was secured by the asset. In accordance with the transaction, all charges in the associated lawsuits have been dismissed.
In addition to the dissolution of DDR’s former joint venture with Coventry, the Corporation also sold 10 assets totaling $104 million at the Corporation’s share. DDR is under contract to sell an additional seven assets totaling $80 million at the Corporation’s share.
DDR Corp. is an equity real estate investment trust. It invests in the real estate markets of the United States and Puerto Rico. The firm is in the business of acquiring, owning, developing, redeveloping, expanding, leasing and managing shopping centers. It formerly known as Developers Diversified Realty Corp. DDR Corp is based in Beachwood, Ohio.
At the end of Tuesday’s trade, Vonage Holdings Corporation (NYSE:VG)’s shares dipped -1.96%, and closed at $4.99, as on April 1, a leading provider of cloud communications services for consumers and businesses, has accomplished the attainment of Simple Signal Inc., a leading provider of Unified Communications-as-a-Service (UCaaS) and partnership solutions to small and medium businesses (SMBs). Vonage paid $25.25 million for SimpleSignal, comprised of about $20 million in cash and about 1.1 million shares in Vonage ordinary stock.
Mr. Gilbert will join Vonage as a special advisor working closely with Vonage administration through the merger integration.
Vonage Holdings Corp. provides unified communications as a service solutions connecting people through cloud-connected devices worldwide. The corporation offers home telephone replacement services to residential customers through various service plans with basic features, such as voicemail, call waiting, call forwarding, simulring, visual voicemail, and extensions, in addition to area code selection, virtual phone number, and Web-enabled voicemail.
BioMed Realty Trust Inc. (NYSE:BMR), ended its Tuesday’s trading session with -1.96% loss, and closed at $22.06, after a real estate investment trust (REIT) firm declared the signing of a 295,000 square foot lease at 675 West Kendall by Alnylam Pharmaceuticals in Cambridge, Massachusetts providing Alnylam with Class A laboratory and office space in the heart of Kendall Square.
Alnylam Pharmaceuticals is leading the translation of RNAi as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. This growing life science corporation will occupy all the rentable space accessible on the six floors of 675 West Kendall when the lease with the current tenant, Vertex Pharmaceuticals, ends in May 2018.
BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT) that focuses on providing real estate to the life science industry in the United States. Its tenants primarily comprise biotechnology and pharmaceutical companies, scientific research institutions, government agencies, and other entities involved in the life science industry.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
